MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include a full text ...
CD20 × CD3 bispecific antibodies bind to both CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity, which triggers T cell-mediated killing of the targeted B cells. CD20 × ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results